Navigation Links
Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial
Date:12/10/2007

NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- Vanderbilt Medical Center is seeking local residents with type 2 diabetes who are overweight to participate in a national clinical study evaluating an investigational device, the TANTALUS System. Diabetes affects more than 400,000 individuals in Tennessee.

The TANTALUS System is an implantable device that delivers electrical pulses to the stomach when a person eats. The primary objective of the randomized, double-blind controlled study is to evaluate the safety and efficacy of the TANTALUS System in treating patients who have type 2 diabetes and are overweight. Impact on weight loss, blood pressure and other clinical and metabolic parameters will also be studied.

TANTALUS includes a pulse generator and leads that are implanted through a minimally invasive laparoscopic procedure that can be performed in an outpatient setting. The leads are implanted in the gastric muscle and the device is implanted in a subcutaneous pocket. The system is based on new technology called Gastric Contractility Modulation (GCM) that is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation treatment during meal times.

To be considered for the trial, patients must meet certain inclusion criteria, including a diagnosis of type 2 diabetes (treated with oral medications, only), a body mass index (BMI) between 28 and 45, and be between 18 and 70.

"Even with current medications and lifestyle changes, controlling blood glucose levels in type 2 diabetes patients who are overweight can be difficult, " explained study investigator William Richards, M.D. "We are excited to be participating in this clinical trial of an alternative treatment for patients where we have been unsuccessful in managing their type 2 diabetes and weight."

The national epidemic of type 2 diabetes, most often associated with being overweight, continues to accelerate and affects more than 20 million Americans. About 1 million new people are diagnosed with the disease annually. Each year, it costs the nation more than $130 billion in hospitalizations, co- morbidities and loss of productivity.

For more information on and to be considered for the study, please call Joan Kaiser at (615) 343-5821.

For More Information:

Jerry Jones

(615) 322-4747

jerry.jones@vanderbilt.edu


'/>"/>
SOURCE Vanderbilt Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):